Alkermes (NASDAQ:ALKS – Get Free Report) and Aprea Therapeutics (NASDAQ:APRE – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends.
Institutional & Insider Ownership
95.2% of Alkermes shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Comparatively, 10.5% of Aprea Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Valuation and Earnings
This table compares Alkermes and Aprea Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alkermes | $1.48 billion | 5.31 | $241.66 million | $0.38 | 123.02 |
| Aprea Therapeutics | $290,000.00 | 32.91 | -$12.60 million | ($1.08) | -0.70 |
Alkermes has higher revenue and earnings than Aprea Therapeutics. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for Alkermes and Aprea Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alkermes | 1 | 4 | 12 | 1 | 2.72 |
| Aprea Therapeutics | 1 | 1 | 3 | 0 | 2.40 |
Alkermes currently has a consensus price target of $54.56, suggesting a potential upside of 16.72%. Aprea Therapeutics has a consensus price target of $3.07, suggesting a potential upside of 304.57%. Given Aprea Therapeutics’ higher possible upside, analysts plainly believe Aprea Therapeutics is more favorable than Alkermes.
Risk & Volatility
Alkermes has a beta of 0.31, suggesting that its stock price is 69% less volatile than the S&P 500. Comparatively, Aprea Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500.
Profitability
This table compares Alkermes and Aprea Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alkermes | 3.96% | 4.15% | 2.19% |
| Aprea Therapeutics | -4,405.59% | -47.60% | -40.97% |
Summary
Alkermes beats Aprea Therapeutics on 11 of the 15 factors compared between the two stocks.
About Alkermes
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
About Aprea Therapeutics
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.
